| IMMUNIC INC. DL-,0001 |
| USA |
| Gesundheit |
| US4525EP1011 / A2PHD4 |
| 10VA (Frankfurt) / IMUX (NASDAQ) |
| FRA:10VA, ETR:10VA, 10VA:GR, NASDAQ:IMUX |
| - |
| https://www.immunic-thera.. |
|
Immunic Inc. is a late-stage biotechnology company developing a pipeline of selective oral immunology therapies for chronic inflammatory and autoimmune diseases, with a focus on neurologic and gastrointestinal conditions. Its lead program, vidofludim..
>Volltext.. |
| 129.98 Mio. EUR |
| 117.29 Mio. EUR |
| - |
| -89.28 Mio. EUR |
| -84.18 Mio. EUR |
| -0.65 EUR |
| 0.5 Mio. EUR |
| 13.41 Mio. EUR |
| -74.33 Mio. EUR |
| 0.51 |
| - |
| 14.78% |
| - |
| - |
| - |
| - |
| IMMUNIC |
| 04.04.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|